KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Other financing activities (2017 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Other financing activities for 8 consecutive years, with -$1787.0 as the latest value for Q3 2025.

  • Quarterly Other financing activities rose 72.16% to -$1787.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$110783.0 through Dec 2025, up 73.67% year-over-year, with the annual reading at -$110783.0 for FY2025, 73.67% up from the prior year.
  • Other financing activities hit -$1787.0 in Q3 2025 for Inovio Pharmaceuticals, up from -$34777.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of -$1787.0 in Q3 2025 to a low of -$4.6 million in Q4 2021.
  • Historically, Other financing activities has averaged -$560957.2 across 4 years, with a median of -$54498.0 in 2025.
  • Biggest five-year swings in Other financing activities: crashed 643.62% in 2024 and later surged 85.52% in 2025.
  • Year by year, Other financing activities stood at -$4.6 million in 2021, then soared by 99.79% to -$9650.0 in 2023, then surged by 33.49% to -$6418.0 in 2024, then surged by 72.16% to -$1787.0 in 2025.
  • Business Quant data shows Other financing activities for INO at -$1787.0 in Q3 2025, -$34777.0 in Q2 2025, and -$74219.0 in Q1 2025.